• Reports

      Reports

      Stay ahead and make informed decisions with Delvens insightful analysis on key business and technological trends.

      How We Can help you
      • Healthcare
      • Automotive
      • Chemicals & Materials
      • Aerospace & Defense
      • Semiconductors & Electronics
      • Food & Beverages
      • Pharmaceutical
      • IT & Telecom
      • Energy
      • Consumer Goods & Services
  • Best Practice Guide

      Best Practice Guides

      The Delvens Best Practice Team offers practical tactics, procedures, and resources to help you address the major growth-related dos and don'ts.

      How We Can help you
      • Healthcare
      • Automotive
      • Chemicals & Materials
      • Aerospace & Defense
      • Semiconductors & Electronics
      • Food & Beverages
      • Pharmaceutical
      • IT & Telecom
      • Energy
      • Consumer Goods & Services
  • Expertise

      Expertise

      Delvens' decades of experience helps you to strategize, plan, optimize and win.

      See What we can do
      • Syndicated Research
      • Custom Research
      • Consulting
      • Implementation Support
      • Audio-Video Infographic Workshops
      • Subscription Model
      • Bundle Reports Model
      • Best Practice Guides
  • Innovation

      Innovation

      Gain thought-provoking insights on some of the biggest trends in the world to guide you in the phase of innovation.

      Let's Innovate

      Latest Chronicles

      Pharma Businesses

      Pharma businesses that are rewired will win in the digital era

      13th July 2023

      Featured Chronicle

      ESG

      Why ESG is more important than ever!

      4th November 2022
  • Innovation
  • Explore

      Explore

      From accelerating growth and providing strategic vision to the world's biggest brands, to lunch-break sneaker shopping on Melrose, and thirsty Thursdays at the local pubs. We have a Hustling atmosphere because growing together should be fun, or why do it?

      Let's Explore Something

      About

      • Who We Are
      • Why Choose Us
      • Research Methodology
      • Careers
      • Contact

      Help

      • Customer FAQs
      • How To Order
      • Delivery Method
      • Return Policy
      • Privacy Policy
      • Terms of Use
  • Newscast

      Blogs

      The Pros and Cons of Cloud Computing

      The Pros and Cons of Cloud Computing

      13th July 2023
      Let's Read

      Press Room

      Healthcare AI Innovation

      Healthcare AI innovation: a new era of patientcare

      13th July 2023
      Let's Understand

      Article

      Electric Vehicle Thermal Management System (EVTMS) Market

      19th May 2023
      Let's Study
  • Newscast
      • Blog
      • Article
      • Pressroom
Pharmaceutical Icon

Cardiovascular Drugs Market – Trends Forecast Till 2030

Cardiovascular Drugs Market, by Drug Class (Anti-hyperlipidaemic, Anti-hypertensives, Anti-coagulants, Anti-arrhythmic and Others), Indication (Hypertension, Hyperlipidaemia, Coronary Artery Disease, Arrhythmia and Others), Distribution Channel (Hospital, Pharmacies and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

  • Published Date : August 2023
  • Base Year Estimate : 2022
  • Report ID : D-PH-CDM-1480
  • Format :
  • Number of Pages : 470
  • Domain : Pharmaceutical
  1. Pharmaceutical
  2. Cardiovascular Drugs Market – Trends Forecast Till 2030
Buy Now Get Free Sample Now
REPORT SYNOPSIS
Market Snapshot Market Overview Delvens Industry Expert's Standpoint Market Portfolio Key Findings Regional Analysis Competitive Landscape Recent Developments Reasons to Acquire Report Scope
Table Of Content Frequently Asked Questions

Market Snapshot

Market Overview

The Cardiovascular Drugs market size was estimated at USD 168.36 billion in 2023 and is projected to reach USD 221.85 billion in 2030 at a CAGR of 4.02% during the forecast period 2023-2030.

Cardiovascular drugs are medications that are used to treat various conditions related to the heart and blood vessels. They are prescribed to manage heart diseases and other cardiovascular disorders. Cardiovascular medicines are often used in combination to treat different aspects of a cardiovascular disease. There are various types of cardiovascular drugs such as antihypertensives that are used to lower blood pressure, anticoagulants that are used to prevent blood clots, antihyperlipidemic that are used to lower cholesterol and triglyceride levels, antiarrhythmics that are used to regulate abnormal heart rhythms. Most cardiovascular drugs are prescribed to treat hypertension and dyslipidaemia which are majorly responsible for the formation of atherosclerotic plaque within blood vessels restricting blood flow to the body parts resulting in multiple cardiac indications such as stroke, heart failure, cardiomyopathy, peripheral artery disease, and venous thrombosis.

The cardiovascular drugs market can be segmented based on drug class into anti-hyperlipidaemic, anti-hypertensives, anti-coagulants, anti-arrhythmic and others. Based on indication the market can be bifurcated into hypertension, hyperlipidaemia, coronary artery disease, arrhythmia and others. Based on distribution channel, the market can be segmented into hospital, pharmacies and others. Lastly, based on region the market is bifurcated into North America, Europe, Asia-Pacific, Middle East and Africa and South America. Rising prevalence of cardiovascular diseases (CVDs) globally, growing research and development and investment in efficient drug development and increasing availability of reimbursement policies are the factors that are contributing to the growth of the market during the forecast period. Moreover, the increasing number of admissions in hospitals, as well as critical care units owing to cardiovascular diseases (CVDs) has created demand for the development of cardiovascular drugs for treatment.

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cardiovascular diseases to significant risks. However, the demand for cardiovascular drugs increased during the pandemic owing to the increased risk of infection among patients with cardiovascular diseases (CVDs).

Delvens Industry Expert's Standpoint

During the pandemic, increased risk of infection among patients with CVDs led to an increase in the demand for cardiovascular drugs which drove the market during the pandemic. The cardiovascular drugs market is further expected to grow during the forecast period. This growth can be attributed to factors such as growing research and development, increased investment in efficient drug development and increasing availability of reimbursement policies. In addition to that, increasing prevalence of cardiovascular diseases among the population leading to increase in number of admissions in hospitals as well as critical care units has led to increased demand for cardiovascular drugs for treatment.

Market Portfolio

Key Findings

  • Based on drug class the market can be segmented into anti-hyperlipidaemic, anti-hypertensives, anti-coagulants, anti-arrhythmic and others. The anti-hypertensives dominated the market in this segment and is expected to continue to dominated the market during the forecast period, due to the high prevalence of stress, anxiety and hypertension among people.
     
  • Based on indication, the market can be bifurcated into hypertension, hyperlipidaemia, coronary artery disease, arrhythmia and others. The hypertension segment dominated the market in this segment and garnered the highest share. It is expected to dominate the cardiovascular drugs market during the forecast period due to increased target population suffering from hypertension, and increasing product approvals.
     
  • On the basis of distribution channel, the market can be segmented into hospitals, pharmacies and others. The hospitals segment dominated the market in this segment which can be attributed to the high demand for cardiovascular drugs in the hospital.
     
  • The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. This can be attributed to several factors such as sedentary lifestyle of people in the region, improper diet, stress and anxiety. Moreover, increasing level of product launches, approvals and clinical trials is driving the growth of the market.

Regional Analysis

North America to Dominate the Market

  • North America is estimated to account for the largest market share during the forecast period. Lack of physical activity leading to a sedentary lifestyle, improper diet, stress and anxiety are resulting in chronic diseases such as diabetes and obesity leading to rising in the prevalence of multiple cardiovascular diseases like coronary artery disease, strokes, and atrial fibrillation.
     
  • In addition to that, product launches, approvals, and clinical trials are increasing in the region which is expected to drive the growth of the market during the forecast period.

 

Competitive Landscape

  • Amgen Inc
  • Baxter
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Johnson & Johnson
  • Lupin
  • Merck & Co., Inc. (MSD)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S A
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Janssen Pharmaceuticals, Inc.
  • Daiichi Sankyo
  • Portola Pharmaceuticals
  • United Therapeutics Corp